普拉西尼祖马布减缓了快速进展的早期帕金森病的运动进展
Gennaro Pagano1,2, Kirsten I Taylor3, Judith Anzures Cabrera4
1Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland. Gennaro.Pagano@Roche.com.
Nature medicine
|April 15, 2024
概括
在疾病进展较快的患者中,prasinezumab可能更有效地减缓帕金森病的运动进展. 这一发现需要在额外的临床试验中进行进一步的研究,以确认在特定患者亚组中的疗效.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 是一种进展性神经退行性疾病,其特点是运动和非运动症状.
- 阿尔法-同核素聚合是PD的关键病理标志.
- 普拉西尼祖马布是一种向聚合α-synuclein的单克隆抗体,正在评估其在早期PD的疾病修饰潜力.
研究的目的:
- 探索prasinezumab在减缓帕金森病早期运动信号进展方面的疗效.
- 评估prasinezumab是否在特定的患者亚组中表现出更快的疾病进展,显示出更大的益处.
- 分析各种预先规定的和探索性子群体的治疗效应.
主要方法:
- 该研究分析了PASADENA第二阶段临床试验的数据.
- 根据药物使用,疾病严重程度和临床亚现象型等因素,对预规定的和探索性亚群进行了亚群分析.
- 主要使用运动障碍学会统一帕金森病评级表 (MDS-UPDRS) 的第三部分进行了评估.
主要成果:
- 虽然PASADENA研究的主要终点未达到,但与安慰剂相比,普拉西内祖马布显示运动进展缓慢的趋势 (MDS-UPDRS Part III).
- 一项探索性分析表明,prasinezumab对减缓运动进展的影响在快速进展的亚组中更为明显,例如那些患有扩散恶性亚表型或在基线使用单胺氧化酶B抑制剂的人群.
- 这些发现表明基于疾病进展速度的潜在差异性治疗效果.
结论:
- 普拉西尼祖马布在减缓帕金森病患者的运动进展方面可能具有更大的益处,病变轨迹更快.
- 观察到的效应在特定子组中更为显著,需要进一步调查.
- 需要进行额外的随机临床试验来验证这些后期发现,并确认prasinezumab在向帕金森病患者群体中的有效性.
相关概念视频
01:24Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
01:15Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
01:22Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
01:37Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
01:20Antiepileptic Drugs: Potassium Channel Activators
176
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
176